Drugs / JMKX003948
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06832657 | Feb → Dec 2025 overdue | age-related macular degeneration, diabetic macular edema | Jemincare | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06321250 | Mar 2024 → May 2026 overdue | renal cell carcinoma | Jemincare | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JMKX003948 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06321250 ↗ |